Voltage-dependent calcium channels at the heart of pain perception;Les canaux calciques dépendants du voltage au cœur de la douleur

Medecine/Sciences

Volumn 22, Issue 4, 2006, Pages 396-404

  Weiss, Norbert ^a   De Waard, Michel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AM 336; AMILORIDE; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL R TYPE; CALCIUM CHANNEL T TYPE; DIHYDROPYRIDINE DERIVATIVE; ETHOSUXIMIDE; GABAPENTIN; MIBEFRADIL; MORPHINE; NICKEL; NIFEDIPINE; OMEGA AGATOXIN IVA; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIA; OMEGA CONOTOXIN MVIIC; PHENYLALKYLAMINE; UNCLASSIFIED DRUG;

ANALGESIA; ANXIETY DISORDER; ASTHENIA; CALCIUM TRANSPORT; CHRONIC PAIN; CONSTIPATION; DIABETIC NEUROPATHY; DRUG HYPERSENSITIVITY; ELECTROPHYSIOLOGY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERTENSION; ION CONDUCTANCE; MEMORY DISORDER; MIGRAINE; NAUSEA; NERVE CELL EXCITABILITY; NEUROLOGIC DISEASE; NEUROPATHY; NOCICEPTION; OPIOID INDUCED EMESIS; POSTHERPETIC NEURALGIA; REVIEW; SIGNAL TRANSDUCTION; SOMNOLENCE; SYNAPTIC TRANSMISSION; TRIGEMINUS NEURALGIA; VERTIGO; VISUAL DISORDER;

EID: 33645837456     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2006224396     Document Type: Review

References (52)

1. Craig AD. A new view of pain as a homeostatic emotion. Trends Neurosci 2003; 26: 303-7.
2. Julius D, Basbaum Al. Molecular mechanisms of nociception. Nature 2001; 413: 203-10.
3. Craig AD. Pain mechanisms: labeled lines versus convergence in central processing. Annu Rev Neurosci 2003; 26: 1-30.
4. McCleskey EW, Gold MS. Ion channels of nociception. Annu Rev Physiol 1999; 61:835-56.
5. Meir A, Ginsburg S, Butkevich A, et al. Ion channels in presynaptic nerve terminals and control of transmitter release. Physiol Rev 1999; 79: 1019-88.
6. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000; 25: 533-5.
7. 2+ channels. Neuroreport 2001; 12: 2423-7.
8. 2+ channel. EMBO J 2001; 20: 2349-56.
9. Kerr LM, Yoshikami D. A venom peptide with a novel presynaptic blocking action. Nature 1984; 308: 282-4.
10. Olivera BM, Cruz LJ, de Santos V, et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987; 26: 2086-90.
11. Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995; 60: 83-90.
12. Chaplan SR, Pogrel JW, Vaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994; 269: 1117-23.
13. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial JAMA 2004; 291: 63-70.
14. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000; 85: 291-6.
15. Adams DJ, Smith AB, Schroeder CI, et al. Omega-conotoxin CVID inhibits a pharmacologically distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve terminals. J Biol Chem 2003; 278: 4057-62.
16. Smith MT, Cabot PJ, Ross FB, et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002; 96: 119-27.
17. Blake DW, Scott DA, Angus JA, Wright CE. Synergy between intrathecal omega-conotoxin CVID and dexmedetomidine to attenuate mechanical hypersensitivity in the rat. Eur J Pharmacol 2005; 506: 221-7.
18. Seko T, Kato M, Kohno H, et al. Structure-activity study of L-cysteine-based N-type calcium channel blockers: optimization of N- and C-terminal substituents. Bioorg Med Chem Lett 2002; 12: 915-8.
19. Teodori E, Baldi E, Dei S, et al. Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain. J Med Chem 2004; 47: 6070-81.
20. Bell TJ, Thaler C, Castiglioni AJ, et al. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 2004; 41: 127-38.
21. Seward E, Hammond C, Henderson G. Mu-opioid-receptor-mediated inhibition of the N-type calcium-channel current. Proc Biol Sci 1991; 244: 129-35.
22. De Waard M, Liu H, Walker D, et al. Direct binding of G-protein betagamma complex to voltage-dependent calcium channels. Nature 1997; 385: 446-50.
23. Zamponi GW, Bourinet E, Nelson D, et al. Crosstalk between G proteins and protein kinase C mediated by the calcium channel alpha1 subunit. nature 1997; 385: 442-6.
24. Marker CL, Lujan R, Loh HH, Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids J Neurosci 2005; 25: 3551-9.
25. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002; 7: 235-46.
26. Meunier JC. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol 1997; 340: 1-15.
27. Beedle AM, McRory JE, Poirot O, et al. Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat Neurosci 2004; 7: 118-25.
28. 2+ channel gene CACNL1A4. Cell 1996; 87: 543-52.
29. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003; 4: 386-98.
30. 2+ channel enhanced morphine analgesia and reduced morphine tolerance. Eur J Neurosci 2004; 20: 3516-9.
31. 2+ channel. Proc Natl Head Sci USA 2000; 97: 6132-7.
32. Todorovic SM, Pathirathna S, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal anti-nociception in rats after systemic administration of verapamil. Neurosci Lett 2004; 360: 57-60.
33. Murakami M, Fleischmann B, De Felipe C, et al. Pain perception in mice lacking the beta3 subunit of voltage-activated calcium channels. J Biol Chem 2002; 277: 40342-51.
34. 2+ channel alphal subunit contains an endoplasmic reticulum retention signal antagonized by the beta subunit. Neuron 2000; 25: 177-90.
35. Cuchillo-Ibanez I, Aldea M, Brocard J, et al. Inhibition of voltage-gated calcium channels by sequestration of beta subunits. Biochem Biophys Res Commun 2003; 311: 1000-7.
36. Newton RA, Bingham S, Case PC, et al. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-l subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001; 95: 1-8.
37. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001; 21: 1868-75.
38. Li Cy, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 2004; 24: 8494-9.
39. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Ses 2002; 951: 336-40.
40. Dogrul A, Gardell LR, Ossipov MH, et al. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 2005; 105: 159-68.
41. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004; 109: 150-61.
42. 2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. Mol Pharmacol 2004; 66: 1223-35.
43. 2+ channels in vivo: alteration of nerve injury-induced thermal hyperalgesia. Pain 2004; 109: 328-39.
44. Bourinet E, Alloui A, Monteil A, et al. Silencing of the Ca(v)3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005; 24: 315-24.
45. Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 2005; 107: 139-54.
46. Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des 2005; 11: 2945-60.
47. Eglen RM, Hunter JC, Dray A. Ions in the fire: recent ion-channel research and approaches to pain therapy. Trends Pharmacol Sci 1999; 20: 337-42.
48. Jarvis MF, Burgard EC, McGaraughty S, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA 2002; 99: 17179-84.
49. Vyklicky L, Knotkova-Urbancova H, Vitaskova Z, et al. Inflammatory mediators at acidic pH activate capsaicin receptors in cultured sensory neurons from newborn rats. J Neurophysiol 1998; 79: 670-6.
50. Voilley N. Acid-sensing ion channels (ASICs): new targets for the analgesic effects of non-steroid anti-inflammatory drugs (NSAIDs). Curr Drug Targets Inflamm Allergy 2004; 3: 71-9.
51. Wilson JA, Garry EM, Anderson HA, et al. NMDA receptor antagonist treatment at the time of nerve injury prevents injury-induced changes in spinal NR1 and NR2B subunit expression and increases the sensitivity of residual pain behaviours to subsequently administered NMDA receptor antagonists. Pain 2005; 117: 421-32.
52. Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005; 13: 188-93.